Biologic agents in rheumatology: act II.
نویسنده
چکیده
Division of Rheumatology, Allergy and Immunology, Center for Innovative Therapy (CIT), University of California, La Jolla, USA. Please address correspondence to: Arthur Kavanaugh, MD, Professor of Medicine, Division of Rheumatology, Allergy and Immunology, Center for Innovative Therapy (CIT), University of California, La Jolla, CA 92093-7044, USA. E-mail: [email protected] Received and accepted on February 19, 2010. Clin Exp Rheumatol 2010; 28 (Suppl. 59): S2-S4. © Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2010.
منابع مشابه
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety.
Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations, and, to this end, a systematic literature re...
متن کاملPreoperative Evaluation and Management of Patients Receiving Biologic Therapies
The preoperative care of patients undergoing orthopedic surgery and treated with biologic agents is of great significance.Perioperative use of biologic agents could lead to such complications as infection and delayed postoperative woundhealing. This narrative review aimed to evaluate the current information on the use of biologic agents in patientsundergoing orthopedic surgery...
متن کاملTuberculosis and opportunistic infections: relevance to biologic agents.
With the expanding use of biologic agents, in particular TNF inhibitors, tuberculosis and other opportunistic infections have become an important and growing concern in rheumatology. Clinicians using these therapies should have an understanding of the scope of the problem, the underlying scientific rationale, as well as the optimal approaches to screening, monitoring and treatment.
متن کاملOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
Conventional DMARDs such as MTX are the mainstay of treatment for patients with RA. However, failure to achieve adequate disease control in many patients, even with combination therapy, has spurred the development of agents that target various immune mediators involved in the disease process. In the past decade, biologic agents have proved viable as alternative or add-on therapy to DMARDs in pa...
متن کاملRecommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.
OBJECTIVES To update the 2006 Italian Society for Rheumatology recommendations for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis (PsA). METHODS A panel of experts performed a literature search and identified the items that required updating on the basis of new published data. A draft of the updated recommendations was circulated to a group of Italian Rheu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical and experimental rheumatology
دوره 28 3 Suppl 59 شماره
صفحات -
تاریخ انتشار 2010